[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensionessential\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensionessential":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,70,96,120,147,168,198,229,254],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100401313",false,"NCT04505618","Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease","OCTA-RVD","Exclusion Criteria:\n\n* Both subjects with diseases and controls:\n* Children (age\\\u003C18)\n* Pregnant females\n* Developmentally delayed subjects\n* Subjects unable to provide informed consent\n* Inability to cooperate with tests and study instructions\n* Images with motion artifact or signal strength \\\u003C 7\n* History of glaucoma\n* History of age-related macular degeneration\n* History of any visually significant eye disease\n* History of proliferative diabetic retinopathy\n* History of any inflammatory disease\n* History of heart disease\n* History of thyroid disease.\n* Additional criteria for controls:\n* History of any type of Diabetes Mellitus\n* History of any type of Hypertension",true,"ALL","18 Years","99 Years",{"count":20,"type":21},1050,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.",[27,28,29,30],"Diabetic Retinopathy","Retinal Vein Occlusion","Hypertension,Essential","Retinal Vascular Disorder","RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":35},"2019-10-01",{"date":39,"type":21},"2027-09-01",{"name":41,"class":42},"Johns Hopkins University","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100481279","NCT05546931","Mobile Health Program for Rural Hypertension","Multilevel Mobile Health Program to Improve Rural Hypertension","Inclusion Criteria:\n\n1. History of uncontrolled hypertension, identified from the electronic health record problem list and an average systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits, one of which is within 6 months of study entry\n2. Residence in one of 48 counties categorized as rural by the Center for Rural Pennsylvania;\n3. English-speaking at level appropriate for informed consent and study participation;\n4. No plans to relocate from the area within 12 months of enrollment.\n\nExclusion Criteria:\n\n1. Heart failure necessitating hospital admission ≤3 months prior to study inclusion;\n2. Acute coronary syndrome (defined as at least 2 of the following: chest pain, ischemic electrocardiographic changes, or troponin ≥0.1 ng\u002FmL) ≤3 months prior to study inclusion;\n3. Planned major surgery, cardiovascular or non-cardiovascular;\n4. Pregnancy or planned pregnancy within 12 months;\n5. Presence of non-cardiovascular conditions likely to be fatal within 12 months (e.g., cancer);\n6. Inability to comprehend the study protocol, defined by failing 3 times to answer correctly a set of questions during consent;\n7. Institutionalized status (e.g., nursing home, incarceration);\n8. Inability to operate a smartphone or HBPM device due to sensory or neurocognitive deficit.",{"count":51,"type":21},334,[24],"Hypertension (HTN) is the leading modifiable cause of cardiovascular disease. Rural individuals experience challenges of the rural health divide: geographic distance from providers, social isolation, limited social resources, and high rates of low health literacy. This study evaluates a home-based blood pressure monitoring (HBPM) program that provides longitudinal health education, empathic guidance, monitoring, and adaptable patient-centered coaching to rural individuals. Participants in this study will be randomized to receive (1) HBPM with the intervention; or (2) the control, consisting of HBPM and a smartphone with a general health application (WebMD).",[29,55,56],"Adherence, Medication","Quality of Life",[58,59,60],"hypertension","adherence","rurality","2025-11-16",{"date":63,"type":35},"2025-11-19",{"date":65,"type":35},"2023-09-04",{"date":67,"type":21},"2027-06",{"name":69,"class":42},"University of Pittsburgh",{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":15,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":79,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100444482","NCT05067998","The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature","Inclusion Criteria:\n\n* N\u002FA\n\nExclusion Criteria:\n\n* N\u002FA","21 Years","80 Years",{"count":78,"type":21},25,"1 Week","OBSERVATIONAL","Herbal Medicine is known as the medicinal use of herbal substances as a means of treating different conditions in the human body to ensure that the body remains in optimal health and wellness. These substances are known to contain very active ingredients in it and as such is also a very potent means of managing diseases and ailments in the body.\n\nHerbal medicine has always been a standby source of getting relief from various conditions over centuries, however, it can be categorically said that the mode of usage of these herbal substances has changed over time. Traditional healers help individuals to make meaning out of the natural herbs seen around that can be useful to one's health.\n\nHerbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Herbs can interact with other pharmaceutical medications and should be taken with care. Always seek a regular medical doctor (GP) about any health concerns and tell them about any herbal medicines you are taking or thinking of taking. Never stop taking prescribed medications in favor of herbs without first discussing it with your GP.",[83,84,85,86,29],"Anxiety Disorders and Symptoms","Fibromyalgia","Arthritis","Chronic Pain","2025-09-17",{"date":89,"type":35},"2025-09-23",{"date":91,"type":21},"2025-12-21",{"date":93,"type":21},"2026-09-17",{"name":95,"class":42},"Faith A. Richardson",{"id":97,"slug":4,"hasResults":10,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":10,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100470991","NCT05413057","An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS\u002FAML or FMS\u002FAML\u002FHCTZ","A Multicenter, Prospective, Observational Study to Evaluate Effectiveness and Safety of Fixed-dose Combinations of Fimasartan\u002FAmlodipine or Fimasartan\u002FAmlodipine\u002FHydrochlorothiazide in Essential Hypertensive Patients","* Inclusion Criteria:\n\n  1. Patients who voluntarily consent on the informed consent form and understand the study's purpose, methods, and so on\n  2. Males and females over the age of 19\n  3. Patients who have been diagnosed with essential hypertension and plan to be treated with fimasartan\u002Famlodipine or fimasartan\u002Famlodipine\u002Fhydrochlorothiazide\n\n     If the patient is applicable, one of the following;\n     * If the patients have severe hypertension, stage 2 or higher(sit SBP ≥ 160 mmHg or sit DBP ≥ 100 mmHg), or high-risk hypertension (The cardiovascular risk score of the 2018 hypertension treatment guidelines by the Korean Society of Hypertension is applied.) The patients have never been treated with antihypertensive drugs for essential hypertension.\n     * If the patients are on concomitant administration of fimasartan\u002Famlodipin and hydrochlorothiazide for essential hypertension or, If the patients are on concomitant administration of a fimasartan\u002Fhydrochlorothiazide combination and amlodipine for essential hypertension\n     * If the patients have a blood pressure of sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg even though they have been treated with antihypertensive drugs for essential hypertension\n  4. The patients who understand this study and are available to participate in this study until the end of the study period with a cooperative attitude.\n* Exclusion Criteria:\n\n  1. The patients who are suspected of having secondary hypertension or confirmed to have secondary hypertension\n  2. The patients who are contraindicated to taking fimasartan complex according to the drug labelling\n  3. The patients who are currently participation in another clinical trials (Drugs or medical devices) The patients who took an investigational drug within 12 weeks of the enrollment date\n\n     However, the following patients can participate in this study:\n\n     The patients who are currently enrolled in non-interventional clinical studies or who are being followed up on after the administration of investigational drugs has ended.\n  4. The patients who are not suitable for this study by the investigators","19 Years",{"count":104,"type":21},20000,"The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan\u002Famlodipine or fimasartan\u002Famlodipine\u002Fhydrochlorothiazide, based on fimasartan. (Stage 1).\n\nAlso, this study will evaluate major cardiovascular events, long-term blood pressure control, and the safety by follow-up of those who consent to the extended study for about 2 years (96 weeks).(Stage 2)",[29],[108,109],"Fimasartan","Essentail hypertension","2025-09-10",{"date":112,"type":35},"2025-09-12",{"date":114,"type":35},"2022-06-23",{"date":116,"type":21},"2026-06",{"name":118,"class":119},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"id":121,"slug":4,"hasResults":10,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100301647","NCT03206814","Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System","CHARGE-APP","Inclusion Criteria:\n\n* Male and female subjects;\n* Age 18-80 years;\n* Either the patient or another person close to him\u002Fher should possess a smartphone compatible with the ESH CARE app and be capable of using it;\n* Uncontrolled (untreated or treated) hypertension, defined as office BP ≥140\u002F90 mmHg, and Ambulatory 24h ABP ≥130\u002F80 mmHg\n\nExclusion Criteria:\n\n* eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m2 (CKD-EPI creatinine equation 2009);\n* Severe uncontrolled hypertension (i.e. BP ≥200\u002F120 mmHg despite treatment);\n* Known secondary hypertension;\n* Orthostatic hypotension (SBP fall \\> 20 mmHg on standing);\n* Unstable clinical conditions or severe disease with short life expectation;\n* Known atrial fibrillation;\n* Hepatic disease as determined by either AST or ALT values \\> 2 times the upper limit of normal;\n* History of gastrointestinal surgery or disorders which could interfere with drug absorption\n* History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years;\n* History of clinically significant autoimmune disorders such as systemic lupus erythematosus;\n* History of drug or alcohol abuse within the last 5 years;\n* History of non-compliance to medical regimens and\u002For patients who are considered potentially unreliable;\n* Dementia (clinical diagnosis);\n* Inability or unwillingness to give free informed consent;\n* Inability to use even simple communication technologies;\n* Pregnancy or planned pregnancy during study period",{"count":127,"type":21},480,[24],"The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.",[29,131],"Hypertension, Uncontrolled",[133,134,135,136],"Hypertension","Ambulatory Systolic Blood Pressure","Home Blood Pressure","ESH-CARE APP","2025-02-26",{"date":139,"type":35},"2025-02-27",{"date":141,"type":35},"2021-05-11",{"date":143,"type":21},"2025-12",{"name":145,"class":42},"Istituto Auxologico Italiano",8,{"id":148,"slug":4,"hasResults":10,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":10,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":43},"100538466","NCT06291207","A Study to Evaluate the Efficacy and Safety of AD-224","A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Essential Hypertension\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patient with Secondary Hypertension\n* Other exclusions applied",{"count":154,"type":21},252,[156],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of AD-224",[29],"2025-02-02",{"date":161,"type":35},"2025-02-04",{"date":163,"type":35},"2024-04-15",{"date":165,"type":21},"2025-07",{"name":167,"class":119},"Addpharma Inc.",{"id":169,"slug":4,"hasResults":10,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":10,"sex":16,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100523303","NCT06093932","Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial","Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled Trial","ESCIHP","Inclusion Criteria:\n\n* Age between 35-65 years old, male or female;\n* Grade 1 essential hypertension;\n* Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;\n* Sign the informed consent;\n\nExclusion Criteria:\n\n* Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg\u002Fdl, eGFR\\\u003C60ml\u002F(min·1. 73m2);\n* Gastrointestinal diseases, which may affect drug absorption;\n* Be allergic to the clinical trial medicine;\n* Pregnant or breastfeeding women, men who plan to give birth within half a year;\n* Combined with other serious primary diseases or malignant tumors;\n* Hyperlipidemia with or without taking lipid-lowering drugs;\n* Combined with left ventricular hypertrophy, ABI \\\u003C 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;\n* Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);\n* Other serious conditions in which is not fit for the study.","35 Years","65 Years",{"count":178,"type":21},100,[180],"PHASE4","The purpose of this study is:\n\n1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.\n2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension.\n3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.",[29],[184,185,186,187],"Songling Xuemaikang Capsules","Vascular remodeling","Grade 1 hypertension","Mild hypertension","2024-08-17",{"date":190,"type":35},"2024-08-20",{"date":192,"type":35},"2024-04-07",{"date":194,"type":21},"2027-12",{"name":196,"class":42},"Xiyuan Hospital of China Academy of Chinese Medical Sciences",5,{"id":199,"slug":4,"hasResults":10,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":10,"sex":16,"minAge":204,"maxAge":17,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":215,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100556108","NCT06520800","Treatment and Handling Severe Obesity-Related Comorbidities in Adolescents Through Exercise","THOR-X","Inclusion Criteria:\n\n* adolescents aged 13 to 18 years;\n* of any gender (including transgender adolescents);\n* with severe obesity (≥3.0 BMI z-score) \\[24\\];\n* with any obesity-related comorbidity (e.g., hypertension, IR or DMT2, dyslipidemia, eating disorders, depression\u002Fanxiety);\n* at least 6 months of follow-up at the Pediatric Obesity Clinic (HSM, CHULN) at the time of recruitment;\n* living in Lisbon area;\n* informed consent\u002Fassent signature.\n\nExclusion Criteria:\n\n* major or unstable clinical conditions (other than obesity or its related comorbidities);\n* inability to perform regular PA;\n* pregnancy;\n* mental disorders;\n* smoking habits;\n* being involved in another weight loss program.","13 Years",{"count":206,"type":21},24,[24],"The main objective of this project is to analyze the effect of a tailor-made, one-to-one, exercise program (aiming to treat and handle obesity-related comorbidities in adolescents with severe obesity at high risk of cardiovascular disease development) on BMI z-score, specific comorbidities, and other health-related indicators.\n\nThis project will further allow to analyze the long-term impact of the exercise program not only on clinical parameters, but also on the interaction with drug-treatment, health-related behaviors, and quality of life, further contributing to the understanding of the individual characteristics associated with a positive exercise response and frequency.\n\nThe secondary objective of the THOR-X project is to build an educational toolkit, based on project results and relevant literature, addressed to health and exercise professionals, in order to improve management of adolescents with obesity, in particular those with severe obesity.",[210,29,211,212,213,214],"Adolescent Obesity","Non-Alcoholic Fatty Liver Disease","Dyslipidemias","Metabolic Disease","Metabolic Syndrome",[210,216,217,218],"Obesity treatment","Physical activity","Exercise","NOT_YET_RECRUITING","2024-07-25",{"date":222,"type":35},"2024-07-29",{"date":224,"type":21},"2025-01",{"date":226,"type":21},"2028-12",{"name":228,"class":42},"University of Lisbon",{"id":230,"slug":4,"hasResults":10,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":43},"100540394","NCT06316271","Endothelial Function in Prehypertension","Endothelial Dysfunction and Cardiovascular Remodeling in Pathophyisiology of Prehypertension","Inclusion Criteria:\n\n* adults of both sexes with normotensive, prehypertensive and grade I hypertension blood pressure values\n\nExclusion Criteria:\n\n* cardiovascular diseases, but grade I hypertension (BP 140-150\u002F90-100 mmHg)\n* diabetes\n* kidney disease\n* cerebrovascular diseases\n* peripheral artery disease\n* taking oral contraceptives or any drugs that could affect the endothelium","69 Years",{"count":237,"type":21},90,"In the frame of this proposal investigators will test the hypothesis that high normal blood pressure (prehypertension; PreHT) induces systemic endothelial dysfunction and endothelial activation in both micro- and macrocirculation, reduces re-endothelialization potential of human endothelial progenitor cells (EPCs) and increases the level of endothelial extracellular vesicles (EVs), which are accompanied by increased oxidative stress level. Furthermore, initial vascular and left ventricle (LV) remodeling contributes to changes in systemic hemodynamics and may be influenced by altered regulatory role of renin-angiotensin system (RAS) and autonomic nervous system (ANS) in PreHT but otherwise healthy individuals. To distinguish high normal blood pressure effect from those considered normal or high, study will be performed in three groups of individuals: prehypertensive (BP 130-139\u002F85-89 mmHg), hypertensive (stage I, BP 140-150\u002F90-100 mmHg), and controls (BP less than or equal to 129\u002F85 mmHg). Altogether, the impairment of normal vascular relaxation mechanisms, endothelial activation as well as vascular and LV remodeling could play crucial role in increased cardiovascular risk and CVDs incidence in PreHT individuals. Moreover, the prognostic significance of assessing endotehlial dysfunction in hypertension (as well as in PreHT) is yet to be established.",[29],[58,241,242,243,244],"prehypertension","endothelium","left ventricle","hemodynamics","2024-03-11",{"date":247,"type":35},"2024-03-18",{"date":249,"type":21},"2024-04-01",{"date":251,"type":21},"2026-12-31",{"name":253,"class":42},"Josip Juraj Strossmayer University of Osijek",{"id":255,"slug":4,"hasResults":10,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":278},"100409569","NCT04613193","Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis","BP-AVALVE","Inclusion Criteria:\n\n* Aortic valve peak velocity (Vmax) of 3.0-5.0 m\u002Fs and\u002For aortic valve area (AVA) ≤ 1.2 cm2\n* Blood pressure: SBP \\>= 127 mmHg measured by BP-TRU\n* LVEF ≥ 50%\n* Age \\> 18 years\n* Safe birth control management (intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)) for women of childbearing potential.\n* Negative urine-HCG for women of childbearing potential\n* Ability to understand the written patient information and to give informed consent.\n\nExclusion Criteria:\n\n* Symptoms due to AS\n* Symptomatic orthostatic hypotension and\u002For one minute standing SBP \\\u003C 110 mmHg (16).\n* Suspicion of secondary hypertension\n* Participation in other randomized drug study (device studies accepted)\n* Moderat to severe aortic valve regurgitation e.g. vena contracta \\> 5 mm, assessed by echocardiography)\n* Known or suspected ischemic heart disease (coronary angiography with \\>70% stenosis in a major epicardial vessel, symptoms or signs of myocardial ischemia, e.g. angina pectoris, wall motion abnormalities). Patients who have previously undergone complete revascularization of major coronary arteries due to angina pectoris are eligible for inclusion.\n* Significant coronary obstructive lesions detected by baseline Cardiac CT that requires a revascularisation procedure.\n* eGFR \\\u003C 30 ml\u002Fmin or end-stage renal disease\n* Other disease, comorbidity or treatment making the subject unsuitable for study participation as judged by the investigator",{"count":261,"type":21},200,[24],"The aim of this study is to investigate the effect of strict blood pressure control versus conventional care in patients with asymptomatic moderate to severe aortic valve stenosis.\n\nThe study is a randomized (1:1), open label, controlled intervention trial.\n\nHypothesis:\n\n1. Strict BP control for 12 months reduces the progression of LV remodelling compared to conventional treatment.\n2. Strict BP control for 2 years reduces the increase in aortic valve calcification and LV remodelling compared to conventional treatment.\n3. Strict BP reduction for up to 10 years reduces the need for aortic valve replacement and cardiovascular events compared to conventional care.",[265,29,266],"Aortic Valve Stenosis","Heart Failure",[265,133,268],"Heart failure","2020-10-27",{"date":271,"type":35},"2020-11-03",{"date":273,"type":35},"2019-03-01",{"date":275,"type":21},"2031-06-01",{"name":277,"class":42},"Henrik Wiggers",6,""]